Share this page!

Bishal Gyawali Profile picture
Twitter logo
11 Apr, 4 tweets, 3 min read
It was my pleasure sharing some thoughts on communication skills in oncology with the participants of @ecancer #Kolkata21 meeting today morning. The video is already available to watch for those interested: ecancer.org/en/video/9670-…
With special thanks to @ChernyNathan @scottrberry and @ramsedhom for providing me advice/thoughts/slides to make this talk possible. I myself learned a lot in this process.
Many thanks to @HealthCommunic2 for organizing the event. Missed meeting all dear friends and colleagues in person, hopefully next year we can.
#globaloncology @QueensUHealth @QueensGlobalOnc

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Bishal Gyawali

Bishal Gyawali Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @oncology_bg

Bishal Gyawali Profile picture
31 Mar
Published just now in @ASCO_pubs JCO Global Oncology. The FIRST report of a population-based cancer registry from Nepal. It felt very meaningful to contribute to this #cancergroundshot project. ascopubs.org/doi/full/10.12… #globaloncology Image
For the first time, we now have official data on the commonest cancers in Kathmandu by incidence and mortality in different subgroups of population. ascopubs.org/doi/full/10.12… Image
The population-based cancer registry has only just started in Nepal, and there are plenty of room for improvement. But I hope this provides the foundation for stronger work in the future. ascopubs.org/doi/full/10.12… Image
Read 4 tweets
Bishal Gyawali Profile picture
11 Mar
Very happy to see this announcement today from @FDAOncology . Early approval based on surrogate and appropriate action upon failure to confirm clinical benefit in confirmatory trial is the mandate of accelerated approval. fda.gov/news-events/fd…
Several of our works @PORTAL_Research have previously highlighted that this follow-through has not been happening. Failure to act when drugs fail to improve clinical benefit in confirmatory trials breaks the social compromise of AA. I will share 2 imp papers in this regard.
First, in this @JAMAInternalMed paper we published last year, we show that confirmatory trials do not confirm clinical benefit using survival endpoints and even when confirmatory trials fail, no actions are usually taken. jamanetwork.com/journals/jamai… @akesselheim
Read 5 tweets
Bishal Gyawali Profile picture
9 Jul 20
This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/
This was my first publication ever. A correspondence to @TheLancetOncol in 2014 about cancer care and research in Nepal with @Poudyalbishesh : thelancet.com/journals/lanon…
This is probably one of the most important papers we’ve ever published. This paper in British Journal of Hematology highlights the story of how Bone Marrow Transplant services started in Nepal under @Poudyalbishesh ‘s initiative. onlinelibrary.wiley.com/doi/full/10.11…
Read 26 tweets
Bishal Gyawali Profile picture
22 Dec 19
Seems like this is the time to look back upon your year. Here’s a thread on my tweets from 2019 that I’d like to share again with the new followers. No particular order. Here’s the first one: medscape.com/viewarticle/91… I learned a lot by reading all the comments to this piece.
The next tweet is a little sad because it’s true:
I hope every December continues to bring good news such as these:
Read 19 tweets
Bishal Gyawali Profile picture
15 Nov 18
There's a great coverage today in @Medscape of our latest @bmj_latest paper. Unfortunately, I'll have to disagree with these comments from an expert which I find disrespectful. RANTORIAL ahead. medscape.com/viewarticle/90…
All 4 authors in our @bmj_latest paper are medical oncologists. It's our daily job to talk to patients about benefits and side effects of cancer drugs. What's the basis for suggesting that we didn't talk to patients? The no. of medical oncologists in the world is ..surprise. >1!
This statement assumes that cancer drugs make a difference between living and dying. I wish that were true, but it's not. This is false dichotomy. It's nearly always a trade-off, not such a clear dichotomy: life with drug, death without drug. Such false dichotomies hurt pts.
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

Like this author's thread?

Get emails when @oncology_bg has new unrolls!

Check out other threads from @oncology_bg!

Read all threads by @oncology_bg